A Phase 1 Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects

EA Pharma Co.,Ltd.0 个研究点目标入组 68 人开始时间: 2016年9月16日最近更新: 2023年10月17日

试验速览

暂无简介。

•(1) Japanese healthy adult males aged >=20 and <45 years at the time of informed consent who are non-smokers or able to stop smoking from at least 4 weeks before study drug administration until the post-treatment examination.
•(2) Has voluntarily consented, in writing, to participate in this study.
•(3) Has been thoroughly briefed on the conditions for participation in the study, and is willing and able to comply with the conditions.

•(1) History of surgical treatment that may affect the pharmacokinetics of the study drug at screening.
•(2) Suspected to have clinically abnormal symptoms or impairment of organ function requiring treatment on the basis of history and complications at screening, and physical findings, vital signs, ECG findings, or laboratory values at screening or baseline.
•(3) History of drug allergy at screening.
•(4) Judged by the investigator or subinvestigator to be inappropriate for participation in this study.

发起方